Trial Profile
Phase I trial of PTI130 for the treatment of cystic fibrosis
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs PTI 130 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 19 Feb 2015 New trial record
- 04 Feb 2015 According to a media release, Proteostasis Therapeutics is expected to file an IND for PTI130 with the US FDA and the drug will enter in phase I trials by the end of 2015.